The legal landscape governing Pharmacy Benefit Managers underwent a tectonic shift when the Supreme Court ruled in Rutledge v. Pharmaceutical Care Management Association that states may regulate pharmacy reimbursement rates without violating ERISA preemption. This landmark 2020 decision effectively dismantled the long-standing defense that federal law shielded Pharmacy Benefit Managers (PBMs) from state oversight, opening a new chapter of legislative activism across the country. By the mid-2020s, this regulatory movement evolved from simple transparency requirements into aggressive structural reforms aimed at addressing the fundamental economic imbalances in the prescription drug supply chain. Independent and specialty pharmacies, which had spent years grappling with unpredictable fees and shrinking margins, found a newfound ally in state legislatures that were increasingly willing to challenge the market dominance of vertically integrated healthcare conglomerates. This evolution reflects a growing recognition that the middleman role once occupied by PBMs has transformed into a powerful gateway that controls patient access, provider viability, and overall healthcare costs.
The Foundation: Judicial Authority and State Oversight
The Impact: Rutledge and the Cost-Regulation Standard
The unanimous decision in Rutledge provided the constitutional bedrock upon which modern PBM regulation is built, clarifying that a state’s attempt to govern the prices paid to pharmacies is not the same as dictating the internal administration of an employer-sponsored health plan. Before this ruling, the industry operated under the assumption that the Employee Retirement Income Security Act (ERISA) acted as a broad shield, preventing any state law from touching anything related to private health insurance benefits. The Supreme Court rejected this expansive view, establishing that cost regulation is a traditional state function that does not necessarily interfere with the uniform administration of federal benefit plans. This distinction has allowed states to enact laws requiring PBMs to reimburse pharmacies at rates that are at least equal to the pharmacies’ acquisition costs, ensuring that local healthcare providers are not forced to dispense life-saving medications at a financial loss.
Building on this foundation, state legislatures have moved to target the specific pricing mechanisms that PBMs use to manage their networks, such as Maximum Allowable Cost (MAC) lists. These lists, which were often opaque and infrequently updated, previously allowed PBMs to capture significant profit margins by paying pharmacies far less than the current market price for generic drugs. Following the precedent set by the Court, states now mandate that these lists be updated frequently and provide a transparent appeals process for pharmacies that are being under-reimbursed. This transition toward objective pricing standards has significantly reduced the volatility of the pharmacy business model, allowing independent owners to plan for the future with greater certainty. The shift represents a move toward a “fair-market” approach where the administrative convenience of the PBM is no longer permitted to override the economic survival of the essential local pharmacy infrastructure.
Judicial Limits: The Mulready Precedent and Federal Preemption
While the authority to regulate costs was firmly established, the legal boundaries were further refined by the Mulready case, which highlighted the areas where federal preemption still holds sway. In this instance, when Oklahoma attempted to impose strict geographic access standards and “any-willing-provider” rules, the courts signaled that states could not overreach into the fundamental design of a health plan’s provider network. The judicial reasoning suggests that telling a health plan exactly which pharmacies must be included in its network—or where those pharmacies must be located—crosses the line from regulating external market costs to interfering with internal plan management. This serves as a vital reminder for policymakers that while they can regulate the price of the transaction, they cannot easily dictate the structural relationship between the payer and its chosen partners without risking a successful ERISA challenge.
This tension between state regulatory ambitions and federal preemption has created a more disciplined approach to legislative drafting, where states must carefully frame their laws as market-wide consumer protection or cost-control measures. The Mulready decision effectively created a safe harbor for PBMs regarding network construction, but it also forced a more creative legislative focus on the behavior of PBMs within those networks. For example, instead of mandating network inclusion, some states have shifted toward regulating the terms of the contracts within those networks, ensuring that even if a PBM chooses a narrow network, the providers within that network are treated with a baseline of fairness. This ongoing legal refinement ensures that the regulatory landscape remains a complex chess match, where each new state law is meticulously scrutinized against the shifting definitions of benefit design versus cost regulation.
Affirming Authority: The Significance of Central States v. McClain
The recent 2026 decision in Central States v. McClain provided a critical affirmation of state power by upholding Arkansas rules that established a mandatory floor for dispensing fees. This ruling was significant because it moved beyond the acquisition cost of the drug and recognized that the professional services provided by pharmacists—such as counseling, storage, and clinical management—also fall under the umbrella of regulatable costs. The court viewed these dispensing fees as a necessary component of the overall price of a medication, rather than a hidden administrative cost of the health plan itself. By validating this approach, the judiciary has given states a clear path to protecting the professional viability of pharmacists, ensuring that the labor and expertise involved in healthcare delivery are fairly compensated in the modern market.
Moreover, the McClain decision was instrumental in legitimizing the extensive reporting requirements that many states have begun to impose on PBMs to ensure compliance with reimbursement laws. The court held that as long as the data collection is incidental to the state’s legitimate interest in cost regulation, it does not create an undue administrative burden that would trigger ERISA preemption. This has paved the way for more robust state-level auditing, where PBMs must disclose their compensation data to state insurance departments. This transparency is no longer viewed as a “nice-to-have” feature of the market but as a necessary enforcement tool that allows regulators to verify that PBMs are not engaging in the very pricing abuses that the Supreme Court sought to address. The result is a more accountable system where the threat of state audit serves as a deterrent against opaque and predatory pricing maneuvers.
Federal Intervention: National Structural Overhauls
Transparency: Reporting Under the Consolidated Appropriations Act
The federal government significantly increased its oversight role through the Consolidated Appropriations Act of 2026 (CAA 2026), which introduced a new era of transparency for the commercial health insurance market. This legislation mandates that PBMs provide highly granular, drug-level data to group health plans every six months, a requirement that finally pulls back the curtain on the complex financial flows that define modern pharmacy benefits. For years, employer plan sponsors were forced to make decisions based on high-level summaries that often obscured the true cost of their pharmacy spend. Under the new federal framework, PBMs must now disclose the specific amounts they receive in manufacturer rebates, administrative fees, and the “spread” between what they charge the plan and what they pay the pharmacy, providing a level of clarity that was previously impossible to obtain.
The impact of this federal reporting requirement extends beyond simple data collection, as it empowers plan fiduciaries to fulfill their legal obligations under ERISA with much greater precision. With access to detailed drug-level information, employers can now identify exactly where their healthcare dollars are going and determine if their PBM is delivering the value it promised. This shift has forced PBMs to move away from “black-box” pricing models toward more transparent, fee-for-service arrangements where their profit is decoupled from the price of the drugs they manage. The CAA 2026 has essentially standardized the language of pharmacy benefit reporting, making it easier for companies to compare different PBM offerings and hold their current partners accountable for every dollar spent. This federal intervention has created a national baseline of transparency that complements the cost-regulation efforts occurring at the state level.
Revenue Reform: The Mandate for Rebate Pass-Throughs
Perhaps the most disruptive component of the CAA 2026 is the national mandate for 100% rebate pass-throughs, a policy that strikes at the heart of the traditional PBM profit model. Historically, PBMs were able to keep a portion of the rebates they negotiated with pharmaceutical manufacturers, creating a perverse incentive to favor higher-priced drugs that offered larger rebates over lower-cost alternatives. By requiring that all manufacturer concessions and fees be remitted back to the health plan, the federal government has effectively removed this incentive, aligning the PBM’s financial interests more closely with those of the plan participants. This reform is designed to lower the net cost of drugs for employer-sponsored plans and, ideally, lead to lower premiums and out-of-pocket costs for the millions of Americans who rely on these benefits.
Furthermore, the CAA 2026 grants employer plan sponsors robust audit rights, allowing them to inspect manufacturer contracts to ensure that every rebate dollar is being accurately accounted for and returned. This move fundamentally changes the relationship between the PBM and the plan sponsor from one of unequal information to one of professional partnership. Before this law, many PBMs considered their manufacturer contracts to be proprietary trade secrets, effectively blocking employers from verifying the accuracy of their rebate checks. Now, the threat of a federal audit ensures that PBMs maintain meticulous records and remain honest in their financial dealings. This structural shift toward a pass-through model is transforming the PBM industry into a service-oriented sector where profitability is driven by administrative excellence and clinical outcomes rather than the clever manipulation of drug prices and manufacturer discounts.
Structural Reform: The Frontier of Ownership Bans
Market Separation: State-Level Ownership Bans and Divestiture
The Tennessee FAIR Rx Act, signed into law in May 2026, represents a bold new frontier in PBM oversight by targeting the very structure of the healthcare industry through ownership bans. This legislation prohibits a single entity from simultaneously owning an insurance company, a PBM, and a pharmacy, a combination often referred to as “tripartite” integration. Proponents of this approach argue that as long as these integrated giants exist, they will always have an inherent financial incentive to steer patients toward their own mail-order or specialty pharmacies while under-reimbursing their independent competitors. By mandating divestiture, Tennessee is attempting to dismantle the vertical silos that many believe have stifled competition and driven up costs in the pharmacy sector, marking a significant departure from previous efforts that only attempted to regulate PBM behavior.
The implementation of this ownership ban has sparked intense legal battles, as major industry players argue that such mandates interfere with their right to conduct business and disrupt the efficiencies they claim vertical integration provides. However, the movement toward structural separation is gaining momentum in other states that view divestiture as the only permanent solution to the conflicts of interest inherent in the current market. These states are watching the Tennessee litigation closely, as it will likely define the extent to which a state can use its police powers to break up integrated healthcare monopolies. If successful, this model could lead to a massive reorganization of the U.S. healthcare landscape, forcing the largest companies to choose a single lane of operation—either as an insurer, a middleman, or a provider—thereby restoring a more traditional and competitive market structure.
Federal Strategy: Legislative Proposals for Market Separation
At the federal level, the debate over structural separation has gained significant traction with the introduction of bills such as the Patients Before Monopolies Act. This proposed legislation seeks to establish a national framework for PBM divestiture, mirroring the Tennessee approach but on a much larger scale. The federal debate focuses on the idea that transparency and fair-reimbursement rules are merely “band-aids” that fail to address the core problem of market consolidation. By proposing a federal ban on PBM ownership of pharmacies, lawmakers are signaling a move toward a more aggressive antitrust stance that prioritizes market competition over corporate integration. This approach is rooted in the belief that the current PBM model has become too large and too complex to be managed through traditional regulatory oversight alone.
The push for federal structural reform is also driven by a desire to simplify the regulatory environment for pharmacies that operate across state lines. Currently, independent pharmacies must navigate a complex patchwork of state laws that vary significantly in their scope and enforcement. A federal divestiture law would provide a uniform standard, ensuring that PBMs cannot use their market power to favor their own affiliated businesses regardless of where the pharmacy is located. While these “break-up” bills face stiff opposition from industry lobbyists, they have found support from a broad coalition of patient advocacy groups, independent pharmacy associations, and employer organizations that are frustrated by the lack of progress in lowering drug costs. This federal legislative strategy represents a high-stakes attempt to reset the pharmacy benefit market by removing the structural incentives that have historically led to anti-competitive behavior.
Regulatory Pressure: FTC and Fiduciary Standards
Economic Analysis: The FTC and Market Power Investigations
The Federal Trade Commission (FTC) has played an increasingly pivotal role in the PBM debate by conducting extensive studies into how market power is utilized by vertically integrated firms. These investigations, often conducted under Section 6(b) of the FTC Act, have produced detailed reports that document the “squeeze” placed on independent pharmacies through aggressive pricing tactics and the steering of patients toward PBM-owned facilities. By using its subpoena power to access internal company communications and financial data, the FTC has been able to prove that the efficiencies claimed by integrated PBMs often do not result in lower costs for consumers or payers. Instead, the agency’s findings suggest that these firms use their gatekeeper status to extract higher fees and protect their own market share at the expense of local providers.
The FTC’s work has provided the empirical foundation that lawmakers and state attorneys general need to pursue more aggressive legal and legislative actions. By highlighting specific practices, such as the use of “exclusionary formularies” that block lower-cost drugs or the manipulation of “specialty pharmacy” definitions to force patients into PBM-owned mail-order programs, the commission has shifted the narrative from one of administrative complexity to one of monopolistic risk. This has emboldened regulators to look beyond simple pricing disputes and consider the broader impact of PBM behavior on the overall health of the American pharmacy infrastructure. The commission’s ongoing scrutiny ensures that PBMs are held to a higher standard of public accountability, making it much more difficult for them to engage in predatory practices without facing significant regulatory pushback.
Legal Standards: Redefining PBMs as Fiduciaries
A significant shift in the legal accountability of PBMs is occurring through the Department of Labor’s movement to treat these entities as fiduciaries under certain conditions. Under the Employee Retirement Income Security Act (ERISA), a fiduciary is held to the highest standard of care in the law, required to act solely in the interest of the health plan and its participants. For decades, PBMs successfully argued that they were merely third-party service providers with no fiduciary obligations, a status that allowed them to engage in practices like spread pricing and the retention of manufacturer rebates without legal repercussion. However, as PBMs have taken on more discretionary authority over drug formularies and clinical management, the argument for fiduciary status has become increasingly difficult to ignore, leading to new rules that demand a higher level of loyalty to the plan.
This reclassification as fiduciaries means that PBMs can no longer legally profit from the “spread” between what they pay a pharmacy and what they charge a health plan unless that compensation is fully disclosed and deemed “reasonable” by the plan sponsor. If a PBM is found to have prioritized its own profits over the savings of the plan, it could face massive legal liability and be forced to return the ill-gotten gains to the plan participants. This threat of fiduciary liability is a powerful tool for employer plan sponsors, who can now demand that their PBM contracts be rewritten to eliminate hidden fees and conflict-of-interest maneuvers. The combination of these new DOL standards and the transparency requirements of the CAA 2026 is creating a much more transparent and ethical environment, where the PBM must prove that its actions are truly in the best interest of the patients it serves.
Strategic Imperatives: Navigating the Healthcare Sector
Operational Resilience: Data-Driven Strategies for Pharmacy Executives
In this era of intense regulatory and legal activity, pharmacy executives have found that their most effective tool for survival is a sophisticated, data-driven approach to reimbursement. Instead of relying on the PBM’s proprietary metrics, successful pharmacies are increasingly using the National Average Drug Acquisition Cost (NADAC), a transparent benchmark published by the Centers for Medicare & Medicaid Services, to demonstrate when reimbursement rates fall below actual costs. By tracking their acquisition and dispensing costs against these objective public standards, pharmacies can provide the “math of the claim” to regulators and lawmakers, making a compelling case for fair reimbursement that is difficult to ignore. This move away from anecdotal evidence toward hard data has been a game-changer in the fight for economic viability, allowing pharmacies to advocate for themselves with unprecedented precision.
Furthermore, pharmacy leaders are focusing on diversifying their revenue streams to reduce their reliance on the traditional PBM-dispensing model, which remains under pressure despite regulatory gains. Many independent and specialty pharmacies are expanding their clinical services, such as chronic disease management, vaccinations, and personalized medicine, which are often reimbursed outside of the PBM framework. By positioning themselves as essential community health hubs rather than just dispensers of pills, these pharmacies are building a more resilient business model that can withstand the ongoing volatility of the drug supply chain. This strategic shift is not just about survival; it is about reclaiming the pharmacist’s role as a vital member of the patient’s care team. Executives who embrace this combination of clinical excellence and data-driven advocacy are the ones best positioned to thrive in the new regulatory environment.
Fiduciary Responsibility: New Obligations for Employer Plan Sponsors
Employer plan sponsors have been forced to recognize that the increased transparency provided by the CAA 2026 carries with it a significant increase in their own fiduciary responsibility. With access to detailed drug-level data, employers can no longer claim ignorance about how their pharmacy benefits are being managed; they now have a legal obligation to audit their PBM arrangements and ensure they are receiving the full value of every rebate and fee. This requires a more hands-on approach to benefit management, where HR and finance executives must actively monitor their Payer-PBM contracts and be willing to challenge their partners when the data reveals inefficiencies or hidden costs. Failure to exercise these new audit rights could potentially expose the employer to litigation from plan participants who believe the company has failed to protect the plan’s assets.
To manage this new responsibility, many employers are turning to independent consultants and legal experts to help them navigate the complexities of PBM auditing and contract negotiation. These experts can help plan sponsors identify “spread pricing” traps, verify rebate pass-throughs, and ensure that the PBM’s clinical programs are truly providing value rather than just steering patients to high-cost drugs. This trend toward active oversight is fundamentally changing the PBM market, as employers move away from a “set it and forget it” mentality toward a model of continuous accountability. By using the tools provided by federal law, plan sponsors are finally taking control of their pharmacy spend, demanding a fairer deal for their companies and their employees, and in the process, helping to drive the entire industry toward a more transparent and cost-effective future.
Policy Drafting: Precision and Future Outlook
The primary lesson for policymakers from the last several years of legal conflict is that legislative success depends on technical precision and a deep understanding of federal preemption boundaries. States that want to protect their local pharmacies must focus their efforts strictly on the regulation of “costs”—such as reimbursement floors, dispensing fees, and audit procedures—to avoid the ERISA preemption traps that have derailed previous attempts at reform. Laws that are written as broad market-wide protections rather than mandates for specific plan designs are much more likely to survive judicial scrutiny. This requires a collaborative effort between legislators, pharmacy associations, and legal experts to craft statutes that are both effective in protecting the pharmacy infrastructure and resilient enough to withstand the inevitable challenges from the PBM industry’s legal teams.
Moving forward, the focus of PBM regulation will likely continue to shift toward structural concerns as the limits of behavioral regulation are reached. Stakeholders successfully adapted to these shifts by prioritizing fiscal transparency and structural integrity. Executives moved beyond reactive legal strategies to embrace proactive auditing and the adoption of standardized acquisition cost models. These actions solidified a more equitable market where clinical outcomes and cost-efficiency finally took precedence over the preservation of opaque profit margins. The next chapter of this evolution will be determined by the outcome of the structural “break-up” laws and the willingness of federal agencies to maintain a high standard of fiduciary accountability. By staying focused on the core goals of fairness, transparency, and patient access, policymakers can ensure that the legacy of these legal battles is a more sustainable and patient-centered healthcare system for all Americans.
